Investigational drug · Phase 3
Eloralintide
Also called: LY3841136
Not approved by FDA. In 13 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Diabetes Mellitus, Type 2.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
13
11 still active
All registered trials
22
Any phase or sponsor naming "Eloralintide"
First trial start
2023
Nov 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Eloralintide", any sponsor or status.
- Phase 110
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
- Diabetes Mellitus, Type 2
- Osteoarthritis
- Overweight or Obesity
- Cardiovascular Diseases
- Sleep Apnea, Obstructive
Approved drugs for the same conditions: Obesity and weight management · Osteoarthritis · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Eloralintide" as an intervention, largest first.
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular RiskPivotal-lookingNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07900633 · 3,000 participants (planned) · Start Dec 2026 · Primary completion Nov 2029
Drug: Eloralintide; Placebo · For: Obesity; Overweight; Cardiovascular Diseases and 1 more
Sites: Birmingham, Alabama; Huntsville, Alabama; Apache Junction, Arizona · 308 sites in all
- A Study of EloraTZP in Adult Participants With Obesity Without Type 2 DiabetesPivotal-lookingNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07881432 · 2,115 participants (planned) · Start Dec 2026 · Primary completion Oct 2029
Drug: eloralintide and tirzepatide; Eloralintide and 2 more · For: Obesity
Sites: Mesa, Arizona; Scottsdale, Arizona; Tucson, Arizona · 161 sites in all
- A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07321886 · 1,980 participants (planned) · Start Feb 6, 2026 · Primary completion Mar 2028
Drug: Eloralintide; Placebo · For: Obesity; Overweight
Sites: Tuscaloosa, Alabama; Scottsdale, Arizona; Escondido, California · 158 sites in all
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06143956 · 1,481 participants (planned) · Start Nov 17, 2023 · Primary completion Sep 2027
Drug: LY3305677; LY3841136 and 5 more · For: Obesity; Overweight
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 57 sites in all
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07282600 · 1,035 participants (planned) · Start Dec 15, 2025 · Primary completion Jan 2028
Drug: Eloralintide; Placebo · For: Overweight; Obesity
Sites: Birmingham, Alabama; Cullman, Alabama; Tucson, Arizona · 143 sites in all
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 DiabetesPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07881458 · 1,000 participants (planned) · Start Oct 16, 2026 · Primary completion Oct 2029
Drug: eloralintide and tirzepatide; Tirzepatide · For: Obesity; Overweight; Diabetes Mellitus, Type 2
Sites: Tucson, Arizona; Escondido, California; Los Alamitos, California · 96 sites in all
- A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07392190 · 900 participants (planned) · Start Feb 10, 2026 · Primary completion Jun 2028
Drug: Eloralintide; Placebo · For: Overweight; Obesity
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 185 sites in all
- Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07353931 · 900 participants (planned) · Start Feb 9, 2026 · Primary completion Mar 2028
Drug: Eloralintide; Placebo · For: Osteoarthritis; Overweight or Obesity
Sites: Mobile, Alabama; Mesa, Arizona; Phoenix, Arizona · 147 sites in all
- A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07369011 · 800 participants (planned) · Start Feb 10, 2026 · Primary completion Mar 2028
Drug: Eloralintide; Placebo · For: Sleep Apnea, Obstructive; Obesity; Overweight
Sites: Cullman, Alabama; Long Beach, California; Los Alamitos, California · 115 sites in all
- A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07589608 · 400 participants (planned) · Start May 15, 2026 · Primary completion Sep 2027
Drug: Macupatide; Eloralintide and 1 more · For: Overweight; Obesity
Sites: Chandler, Arizona; Scottsdale, Arizona; Tucson, Arizona · 40 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.
Panou T, Gouveri E, Popovic DS, et al. · Diabetes Ther 2026
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.
Fischer SL, Borner T · Pharmacol Res 2026
- Cardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism: Emerging Cardiovascular Implications of Eloralintide.
Sigalov A, Frishman WH · Cardiol Rev 2026
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.
Alhazmi A, le Roux CW · Diabetes Obes Metab 2026
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Lempesis IG, Dalamaga M · Metabol Open 2026
- Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.
Kamrul-Hasan ABM, Khalil I, Mahajan K, et al. · Endocrinol Diabetes Metab 2026
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.